Companies news of 2016-05-22 (page 1)

  • comScore Announces Official Worldwide Box Office Results for Weekend of May 22, 2016--...
  • Adaptive Servo-ventilation (ASV) Therapy Suggests Positive Cardiovascular Outcomes for...
  • Allergan Launches 'IBS-D on Tract,' New Online Resource to Support Patients with Irritable...

    comScore Announces Official Worldwide Box Office Results for Weekend of May 22, 2016-- Only comScore Provides the Official Global Movie Results --

    LOS ANGELES, May 22, 2016 /PRNewswire/ -- comScore today announced the official worldwide weekend box office estimates for the weekend of May 22, 2016, as compiled by the company's theatrical measurement services.

    As the trusted official standard for real-time worldwide box office reporting, comScore provides the only theater-level reporting in the world. Customers are able to analyze admissions and gross results around the world using comScore's suite of products.

    comScore's Senior Media Analyst Paul Dergarabedian commented, "An incredibly busy weekend at the global box office was led by Fox's 'X-Men: Apocalypse' with a terrific $103.3 million haul ahead of its North American opening later this week. Sony's 'The Angry Birds Movie' enjoyed a solid international debut a week ago and this weekend along with its North American debut scored a very happy $94.5 million. In other major news, Disney's 'Captain America: Civil War' joined the $1 billion club in global revenue as it rides a wave of great reviews and social media buzz."

    The top 12 worldwide weekend box office estimates, listed in descending order, per data collected as of Sunday, May 22, are below.

    1. X-Men: Apocalypse - 20th Century Fox - $103.3M
    2. Angry Birds Movie, The - Sony - $94.5M
    3. Captain America: Civil War - Disney - $63.8M
    4. Neighbors 2: Sorority Rising - Universal - $27.8M
    5. Jungle Book, The - Disney - $18.4M
    6. Nice Guys, The - Multiple - $12.2M
    7. Divergent Series: Allegiant, The - Multiple - $11.1M
    8. Wailing, The - First Independent Pictures - $11.1M
    9. Money Monster - Sony - $9.9M
    10. Zootopia - Disney - $6.4M
    11. Night Peacock - Multiple - $3.9M
    12. Finding Mr. Right 2 - Multiple - $2.4M

    The top 12 domestic weekend box office estimates, listed in descending order, per data collected as of Sunday, May 22, are below.

    1. Angry Birds Movie, The - Sony - $39.0M
    2. Captain America: Civil War - Disney - $33.1M
    3. Neighbors 2: Sorority Rising - Universal - $21.8M
    4. Nice Guys, The - Warner Bros. - $11.3M
    5. Jungle Book, The - Disney - $11.0M
    6. Money Monster - Sony - $7.1M
    7. Darkness, The - High Top Releasing - $2.4M
    8. Zootopia - Disney - $1.7M
    9. Huntsman: Winter's War, The - Universal - $1.2M
    10. Mother's Day - Open Road - $1.1M
    11. Barbershop: The Next Cut - Warner Bros. - $0.8M
    12. Meddler, The - Sony Pictures Classics - $0.8M

    Full details regarding the global domestic and international box office results are listed in the table below.

    Weekend BO Estimate (USD) Weekend Release Cume (USD) Distributor ------------------------ ------------------------- ----------- Title Worldwide Int'l Domestic Worldwide Int'l Domestic Int'l No. of Terr. Domestic ----- --------- ----- -------- --------- ----- -------- ----- ------------ -------- X-Men: Apocalypse 103,300,000 103,300,000 - 103,300,000 103,300,000 - FOX 75 FOX ----------------- ----------- ----------- --- ----------- ----------- --- --- --- --- Angry Birds Movie, The 94,500,000 55,500,000 39,000,000 151,000,000 112,000,000 39,000,000 SNY 84 SNY ---------------------- ---------- ---------- ---------- ----------- ----------- ---------- --- --- --- Captain America: Civil War 63,814,000 30,700,000 33,114,000 1,053,490,153 706,100,000 347,390,153 DIS 56 DIS -------------------------- ---------- ---------- ---------- ------------- ----------- ----------- --- --- --- Neighbors 2: Sorority Rising 27,787,690 6,000,000 21,787,690 51,787,690 30,000,000 21,787,690 UNI 46 UNI ---------------------------- ---------- --------- ---------- ---------- ---------- ---------- --- --- --- Jungle Book, The 18,417,000 7,400,000 11,017,000 857,697,565 530,200,000 327,497,565 DIS 48 DIS ---------------- ---------- --------- ---------- ----------- ----------- ----------- --- --- --- Nice Guys, The 12,190,000 920,000 11,270,000 12,920,000 1,650,000 11,270,000 MUL 6 WB -------------- ---------- ------- ---------- ---------- --------- ---------- --- --- --- Divergent Series: Allegiant, The 11,120,000 11,000,000 120,000 171,300,028 105,300,000 66,000,028 MUL 6 LGF -------------------------------- ---------- ---------- ------- ----------- ----------- ---------- --- --- --- Wailing, The 11,100,000 11,100,000 - 32,300,000 32,300,000 - FIP 1 WGUI ------------ ---------- ---------- --- ---------- ---------- --- --- --- ---- Money Monster 9,880,000 2,800,000 7,080,000 36,303,647 9,200,000 27,103,647 SNY 17 SNY ------------- --------- --------- --------- ---------- --------- ---------- --- --- --- Zootopia 6,403,000 4,700,000 1,703,000 981,803,528 647,400,000 334,403,528 DIS 26 DIS -------- --------- --------- --------- ----------- ----------- ----------- --- --- --- Night Peacock 3,900,000 3,900,000 - 3,900,000 3,900,000 - MUL 1 - ------------- --------- --------- --- --------- --------- --- --- --- --- Finding Mr. Right 2 2,400,000 2,400,000 - 114,300,000 114,300,000 - MUL 6 ASIA ------------------- --------- --------- --- ----------- ----------- --- --- --- ---- Witch, The 2,100,000 2,100,000 - 35,736,458 10,600,000 25,136,458 UNI 6 A24 ---------- --------- --------- --- ---------- ---------- ---------- --- --- --- Huntsman: Winter's War, The 1,803,540 610,000 1,193,540 157,972,230 111,300,000 46,672,230 UNI 49 UNI --------------------------- --------- ------- --------- ----------- ----------- ---------- --- --- --- Que culpa Tiene el Nino 1,760,000 1,760,000 - 7,750,000 7,750,000 - DMNDF 1 - ----------------------- --------- --------- --- --------- --------- --- ----- --- --- Mother's Day 1,600,214 485,000 1,115,214 42,588,936 11,300,000 31,288,936 MUL 27 OPRD ------------ --------- ------- --------- ---------- ---------- ---------- --- --- ---- Criminal 1,511,000 1,470,000 41,000 32,598,768 17,915,000 14,683,768 MUL 14 LGF -------- --------- --------- ------ ---------- ---------- ---------- --- --- --- Brothers (dir. Gan) 1,300,000 1,300,000 - 1,300,000 1,300,000 - CHINA 1 - ------------------ --------- --------- --- --------- --------- --- ----- --- ---

    *Territory is a movie studio term for regions of the world consisting of various countries.

    (C) 2016 comScore - Content in this chart is produced and/or compiled by comScore and its Box Office Essentials and International Box Office Essentials data collection and analytical services, and is covered by provisions of the Copyright Act. The material presented herein is intended to be available for public use. You may reproduce the content of the chart in any format or medium without first obtaining permission, subject to the following requirements: (1) the material must be reproduced accurately and not in a misleading manner; (2) any publication or issuance of any part of the material to others must acknowledge comScore as the source of the material; and (3) you may not receive any monetary consideration for reproducing, displaying, disclosing or otherwise using any part of the material.

    About comScore

    comScore is the cross-platform measurement company that precisely measures audiences, brands and consumer behavior everywhere. comScore completed its merger with Rentrak Corporation in January 2016 to create the new model for a dynamic, cross-platform world. Built on precision and innovation, our unmatched data footprint combines proprietary digital, TV and movie intelligence with vast demographic details to quantify consumers' multiscreen behavior at massive scale. This approach helps media companies monetize their complete audiences and allows marketers to reach these audiences more effectively. With more than 3,200 clients and global footprint in more than 75 countries, comScore is delivering the future of measurement. For more information on comScore, please visit

    Logo -

    To view the original version on PR Newswire, visit:

    Photo: comScore

    CONTACT: Paul Dergarabedian, Senior Media Analyst, (818) 917-9697,, or Antoine Ibrahim, PR Specialist, (646)

    Web site:

    Adaptive Servo-ventilation (ASV) Therapy Suggests Positive Cardiovascular Outcomes for People with Sleep-Disordered Breathing and Heart Failure With Preserved Ejection Fraction In Phase II StudyTop-line results from ResMed-sponsored CAT-HF study announced at 2016 annual Heart Failure Congress

    FLORENCE, Italy, May 22, 2016 /PRNewswire/-- ResMed today announced primary results from a multicenter, randomized controlled Phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF assessed whether the treatment of moderate to severe sleep-disordered breathing (obstructive or central sleep apnea) with adaptive servo-ventilation (ASV) therapy could improve cardiovascular outcomes in patients who were hospitalized for a sudden worsening of their heart failure symptoms (acute decompensated heart failure) over six months.

    The results of the trial were presented as a late-breaking presentation by Christopher M. O'Connor, M.D., the principal investigator of the study and Chief Executive Officer and Executive Director of the Inova Heart and Vascular Institute.

    Cardiovascular outcomes were defined in the trial by a Global Rank Score primary endpoint that included survival free from cardiovascular hospitalization and improvement in functional capacity as measured by the six-minute walk distance.

    The overall study results were neutral (based on a hazard ratio [HR] =1.07, 95 percent confidence interval [95% CI] = (0.75, 1.51), p-value = 0.717). However, a pre-specified subgroup analysis showed a statistically significant improvement in the primary endpoint for people with heart failure with preserved ejection fraction who have sleep-disordered breathing (based on a HR = 0.38, 95% CI = (0.15, 0.98), p-value = 0.045).

    "These results are important because they are the first to show that addressing sleep-disordered breathing with ASV therapy may improve cardiovascular outcomes for people with preserved ejection fraction heart failure," said ResMed Chief Medical Officer, Glenn Richards, M.D. "We look forward to fully analyzing the results to better understand the role of addressing sleep-disordered breathing in patients with heart failure to determine who would be appropriate candidates for ASV therapy."

    Chronic heart failure occurs when the heart does not pump enough blood to meet the needs of the body. When the heart contracts normally but does not relax sufficiently to fill the chamber with enough blood, it is classified as heart failure with preserved ejection fraction. If the heart cannot contract to pump enough blood, it is heart failure with reduced ejection fraction. Approximately half of people with chronic heart failure have heart failure with preserved ejection fraction.

    CAT-HF is the second randomized controlled ResMed-sponsored study examining the role of treating sleep-disordered breathing in people with heart failure. Last year, results were published from a Phase IV study known as SERVE-HF that showed ASV therapy should not be used for patients with predominant central sleep apnea and symptomatic chronic heart failure with reduced ejection fraction.

    CAT-HF was designed to address a different scientific question of whether cardiovascular outcomes could be improved with ASV therapy after hospitalization for sudden worsening symptoms for people with both preserved and reduced heart failure who also have either obstructive or central sleep apnea.

    "There are no level of evidence 1A guideline recommended therapies specific for heart failure with preserved ejection fraction, which accounts for half of all people living with chronic heart failure," O'Connor said. "These results from CAT-HF suggest we need to study the role of whether addressing sleep-disordered breathing can help people who have heart failure with preserved ejection fraction."

    ResMed is researching how addressing sleep-disordered breathing may help people with cardiovascular diseases, from hypertension and coronary artery disease, to heart failure, atrial fibrillation, and stroke.

    About Sleep-disordered Breathing
    Sleep-disordered breathing encompasses a spectrum of breathing problems during sleep. The two most common types of sleep apnea, a condition that results in repetitive pauses in breathing during sleep, are obstructive sleep apnea and central sleep apnea.

    Obstructive sleep apnea is a sleep disorder in which the throat muscles relax, block the airways and stop the flow of breath during sleep. Central sleep apnea is a sleep disorder in which the brain does not transmit the "breathe" signal to the muscles that control breathing during sleep. In either situation, the lack of oxygen causes the person to wake up to catch their breath and start breathing again, interrupting continuous sleep. This may occur multiple times in an hour.

    Sleep-disordered breathing is found more commonly in patients with heart failure than it is in the general population, and people with heart failure often report poor sleep as a symptom.

    About CAT-HF
    CAT-HF is a randomized controlled trial that evaluated whether adding adaptive servo-ventilation (ASV) to optimized medical therapy could improve cardiovascular outcomes at six months for people with acute decompensated heart failure (HF) patients compared to optimized medical therapy alone. Patients were enrolled with a prior or new diagnosis of heart failure after admission to the hospital with sudden worsening of heart failure symptoms.

    The primary endpoint was cardiovascular outcomes measured as a Global Rank Score of six-minute walk distance, hospitalizations due to cardiovascular issues and death. The study also assessed changes in functional parameters, arrhythmias, biomarkers, quality of life (QoL), and sleep and breathing.

    About ResMed
    ResMed changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 1 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company - improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries. | Facebook | Twitter | LinkedIn

    For News Media For Investors
    Paul McKeon Agnes Lee
    Senior Manager, Corporate Communications Senior Director, Investor Relations
    O: +61-2-8884-2596 O: +1-858-836-5971

    Logo -

    To view the original version on PR Newswire, visit:

    Photo: ResMed Inc.

    Web site:

    Allergan Launches 'IBS-D on Tract,' New Online Resource to Support Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) provides clear information, symptom management strategies and interactive tools for people with IBS-D, which affects up to 15 million adults in the U.S.

    DUBLIN, May 22, 2016 /PRNewswire/ -- Allergan plc today launched, an online resource for those living with irritable bowel syndrome with diarrhea (IBS-D). IBS-D, which affects approximately 15 million adults in the U.S., is a functional bowel disorder commonly characterized by chronic abdominal pain and frequent diarrhea. The new website is a part of Allergan's continued efforts to help educate the public and patients about IBS-D, and includes key information about symptoms, condition management and tips on speaking with a healthcare provider about IBS-D.

    Logo -

    "IBS-D can have a significant impact on patients' daily lives - but in many cases, due to embarrassment or uncertainty about symptoms, patients wait years before seeing a doctor," said Gavin Corcoran, MD, FACP, Chief Medical Officer, Allergan. " is an important resource for patients seeking to better understand the condition and their options. It also helps to explain why talking to their healthcare provider sooner rather than later is critically important, in order to shorten the time between symptom onset and effective disease management."

    According to findings from the American Gastroenterological Association's (AGA) "IBS in America Survey," the most comprehensive IBS survey ever conducted, polling more than 3,200 sufferers and 300 physicians, 66 percent of patients suffer with symptoms for more than a year before talking with a doctor and 11 percent of patients wait a decade or more before seeking medical help. features information that can help patients have a more productive conversation with their healthcare provider, including resources such as a symptom tracker, self-assessment tool and doctor discussion guide.

    For more information about IBS-D and tools for management and treatment, please visit

    About IBS-D

    Irritable bowel syndrome with diarrhea (IBS-D) is a functional bowel disorder characterized by chronic abdominal pain and frequent diarrhea, which affects approximately 15 million patients in the U.S. Although the exact cause of IBS-D is not known, symptoms are thought to result from a disturbance in the way the gastrointestinal tract and nervous system interact.

    IBS-D can be debilitating and there are limited therapeutic options for managing the chronic symptoms. IBS-D is associated with economic burden in direct medical costs and indirect social costs such as absenteeism and lost productivity, along with decreased quality of life.

    About Allergan

    Allergan plc , headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model - Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals and biologic products for patients around the world.

    Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

    With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

    For more information, visit Allergan's website at

    Forward-Looking Statement
    Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the risks associated with acquisition transactions; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (such periodic public filings having been filed under the "Actavis plc" name) and from time to time in Allergan's other investor communications . Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

    CONTACTS: Media

    Mark Marmur
    (862) 261 7558

    Frances DeSena
    (973) 517 3132

    To view the original version on PR Newswire, visit:

    Photo: Allergan plc

    Web site:

    page 1    

    News archive of March 2018
    1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31 

    News Archives of May 2016
    1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31  

    News Archives other dates
    0-C     D-L     M-R     S-Z